Stocks and Investing
Stocks and Investing
Thu, December 22, 2016
[ 01:45 AM ] - United States, WOPRAI
[ 01:45 AM ] - United States, WOPRAI
[ 01:45 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Wed, December 21, 2016
[ 06:45 PM ] - United States, WOPRAI
[ 06:45 PM ] - United States, WOPRAI
[ 04:45 AM ] - United States, WOPRAI
[ 04:45 AM ] - United States, WOPRAI
[ 04:45 AM ] - United States, WOPRAI
[ 01:46 AM ] - United States, WOPRAI
[ 01:46 AM ] - United States, WOPRAI
[ 01:45 AM ] - United States, WOPRAI
[ 01:45 AM ] - United States, WOPRAI
[ 01:45 AM ] - United States, WOPRAI
[ 01:45 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Paul Matteis Initiated (CDTX) at Buy and Held Target at $340 on, Dec 21st, 2016
Paul Matteis of Leerink Swann, Initiated "Cidara Therapeutics, Inc." (CDTX) at Buy and Held Target at $340 on, Dec 21st, 2016.
Paul has made no other calls on CDTX in the last 4 months.
There are 2 other peers that have a rating on CDTX. Out of the 2 peers that are also analyzing CDTX, 0 agree with Paul's Rating of Hold.
These are the ratings of the 2 analyists that currently disagree with Paul
- Ed Arce of "HC Wainwright & Co." Initiated at Strong Buy and Held Target at $500 on, Monday, December 19th, 2016
- Stephen Brozak of "WBB Securities" Downgraded from Hold to Strong Sell on, Friday, September 23rd, 2016
Contributing Sources